Trials / Completed
CompletedNCT04466969
Assessment of Hyperkalemia's Illness and Treatment Burden in Chronic Kidney Disease and Heart Failure Patients: HK Registry Pilot Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 146 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Overall study aim of this study is to analyse descriptive statistics of Patient-Reported Outcome（PROs） which will be used in the Hyperkalemia（HK） registry study in hyperkalemia patients with Chronic Kidney Disease（CKD） or Heart Failure（HF） to describe the practice patterns of hyperkalemia treatment in in clinical practice. Based on these assessments, this study will provide the information for the applicability of PRO measurements which will be used in the Hyperkalemia registry study to the study population, i.e. CKD and/or HF patients with hyperkalemia
Conditions
Timeline
- Start date
- 2020-07-31
- Primary completion
- 2020-11-30
- Completion
- 2020-11-30
- First posted
- 2020-07-10
- Last updated
- 2021-09-13
Locations
5 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04466969. Inclusion in this directory is not an endorsement.